Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

RegFile AB

Noxious parasite forms hybrids and deceives the immune system

The small parasite Trypanosoma cruzi has a nasty ability to cause serious illness. Researchers at the Karolinska Institutet have now mapped its ability to decei...

Study: Chat GPT is more empathetic than doctors

The AI tool Chat GPT is not only more accurate when it comes to answering patient questions – the chatbot is also perceived as almost 10 times more empathetic t...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta...

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

forward and thinking about all the new things that there will be in a freer role,” she says to Life Science Sweden

Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”

Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

19 medicines in Sweden are under investigation in a major EMA inquiry

unless new evidence can be provided that they are up to standard.

Setback for Moderna in patent dispute with mRNA competitors

Moderna has suffered a setback in a patent battle against their worst competitors in covid vaccines, Biontech and its partner Pfizer.

Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

Saving lives worldwide with low-cost molecular diagnostics

High throughput testing for many upper respiratory tract pathogens thanks to automation technology

Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease

According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...

Tirzepatide approved for obesity by the FDA – to be branded as Zepbound

Diabetes drug tirzepatide has now also been approved in the US for treating obesity.

Small robots to deliver pharmaceuticals to the body

Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Bio-Works

He is heading a new company for the development of Coegin’s cancer drug

The biotechnology company Coegin Pharma places the development of its drug candidate AVX420 in a newly formed company, Avexxin Oncology, based in Norway, and Jo...